Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras
about
Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsStereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategyIndividual S-acylated cysteines differentially contribute to H-Ras endomembrane trafficking and acylation/deacylation cycles.Chemical-biological exploration of the limits of the Ras de- and repalmitoylating machinery.Identification of palmitoyltransferase and thioesterase enzymes that control the subcellular localization of axon survival factor nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2)Preclinical efficacy of MEK inhibition in Nras-mutant AML.Combining cross-metathesis and activity-based protein profiling: new β-lactone motifs for targeting serine hydrolasesAcyl protein thioesterase inhibitors as probes of dynamic S-palmitoylation.Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5.Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers.Targeting oncogenic Ras signaling in hematologic malignancies.Profiling and inhibiting reversible palmitoylationAcyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cellsDefective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivoFat chance! Getting a grip on a slippery modification.Searching for the Chokehold of NRAS Mutant Melanoma.How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.A mechanism regulating G protein-coupled receptor signaling that requires cycles of protein palmitoylation and depalmitoylation.S-palmitoylation regulates biogenesis of core glycosylated wild-type and F508del CFTR in a post-ER compartment.Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?Turning the tide in myelodysplastic/myeloproliferative neoplasms.Ras palmitoylation is necessary for N-Ras activation and signal propagation in growth factor signalling.Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic KrasPosttranslational Modifications of RAS Proteins.Protein depalmitoylases.The role of S-acylation in protein trafficking.Targeting Ras signaling in AML: RALB is a small GTPase with big potential.RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation
P2860
Q27027458-4F510E2F-679A-4D5A-B4EF-0516D1DB59A6Q27682798-51CEC2F2-D8AE-40C4-B1D0-3FA803006AE0Q30844739-3EB34265-22DF-42BB-B503-48B4E93F8026Q34266996-D55520C2-DE4C-42E3-A727-C8B465C999B6Q34552744-EA5933B8-431C-41F5-A25C-9B391DE0D3EBQ34737521-696ABCAF-DE72-4470-895C-B2E1F87748EEQ34785627-CB15FFAD-A71E-420E-AC66-B080C0CEA4D8Q34789296-E1184DDC-5AAE-47D2-829B-F08A6A944E43Q35434177-F5D3BA34-12C8-461E-B7F8-C9DE1309F8C2Q35746623-6BEA8799-95CB-49D9-938B-7A1E24B68A50Q36352506-5780604A-9F15-49CF-9AB9-E9C5BFD702BDQ36673837-59C0ACC2-3D97-4A56-AAF4-1517CA0D859EQ36916468-1A1F9DD0-481C-4A4C-A1C4-F856DA631720Q36928333-D76F38F0-CEAA-4F6F-BDC3-636C2EB85E76Q36957153-C2FF47C0-D7B2-4DC3-8AAA-BD5C74817044Q37038604-C93662AD-C8FA-4151-A37B-6813F9196B26Q37113976-99D33759-778A-439C-80BA-3EF67070C295Q37608581-0D00945D-B5AC-4D62-9468-8B6039AD948CQ37712756-A6467622-B094-478E-ADAC-3B1ABEBE6B04Q38423044-62485CA3-ECA9-4F4A-9C06-BCC596A278B9Q38712988-8C3D70F9-B125-48D6-82D6-9A12B054B521Q39140690-9E323AB3-0BC6-48C7-9707-BFC09B2DBC45Q39144248-A6F6B017-07CB-480A-8453-A7F2470C62B0Q42760471-CC311B1C-332D-4117-9A3C-86F125179E98Q47223139-853ABA00-850C-4A36-9911-BABBB7211523Q47295054-EF4301DC-E4CF-4251-BF1C-553F0EFE59C6Q47911502-C124410D-AE15-4317-9137-083EA2411947Q48166242-6E1B2C49-3F1F-4BF6-A51F-C1FF8E8C2FBCQ58763445-833DE7EC-DD79-4ACE-A9A7-656897C3E005
P2860
Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Inhibiting the palmitoylation/ ...... ells expressing oncogenic Nras
@ast
Inhibiting the palmitoylation/ ...... ells expressing oncogenic Nras
@en
type
label
Inhibiting the palmitoylation/ ...... ells expressing oncogenic Nras
@ast
Inhibiting the palmitoylation/ ...... ells expressing oncogenic Nras
@en
prefLabel
Inhibiting the palmitoylation/ ...... ells expressing oncogenic Nras
@ast
Inhibiting the palmitoylation/ ...... ells expressing oncogenic Nras
@en
P2093
P2860
P1433
P1476
Inhibiting the palmitoylation/ ...... ells expressing oncogenic Nras
@en
P2093
Christian Hedberg
Eugene Hwang
Kevin M Haigis
Kevin Shannon
P2860
P304
P356
10.1182/BLOOD-2011-06-358960
P407
P577
2011-12-05T00:00:00Z